Eurofins Expands Presence in Discovery Pharmacology & Bioanalysis by Acquiring the Discovery & Development Solutions Bus. of ...
January 09 2014 - 12:30AM
Business Wire
Regulatory News :
Eurofins Scientific (Paris:ERF) (EUFI.PA), the world leader in
providing analytical support to the pharmaceutical industry,
announces the signing of an agreement to acquire the assets of the
Discovery and Development Solutions (DDS) business of Merck
Millipore (EMD Millipore in the United States and Canada), the Life
Science division of Merck KGaA, Darmstadt, Germany.
DDS is a leading provider of bioanalytical testing and early
stage discovery services and products to the biopharmaceutical
market and generates revenues of about USD 35m with ca. 175
employees from its three sites in St. Charles (Missouri), Dundee
(Scotland) and Oxford (England). For over 35 years, DDS has built a
reputation for high-quality service and reliability while
delivering the most up-to-date drug target assays and bioanalytical
services to match emerging testing needs in the pharmaceutical
industry.
In addition to its renowned discovery pharmacology expertise,
DDS provides industry-leading expertise in bioanalytical testing to
support clinical trials. The acquisition of DDS strengthens
Eurofins’ leading presence in the early stage discovery solutions
market while adding the most advanced expertise in high-quality
bioanalytical services. After the transaction, DDS will continue to
provide products and services to Merck KGaA’s pharma business.
As part of the agreement, Eurofins will retain DDS’
highly-qualified workforce and leadership, and the business will
continue to be led by Christina Shasserre, who has more than ten
years’ experience in the laboratory services market and has been
heading the DDS business since 2010. Ms. Shasserre will be
President of Eurofins Pharma BioAnalytical Services, as the company
will be known following the closing. The transaction is subject to
standard closing conditions, which the parties expect to complete
within 90 days.
Comment from Dr. Gilles Martin, Eurofins CEO: “The addition of
DDS into the Eurofins network reinforces our leading position in
the discovery pharmacology market, and expands our large molecules
bioanalytical service capability to meet the growing needs of our
pharmaceutical and biopharmaceutical clients. The transaction
reflects Eurofins’ commitment to provide the best laboratory
services and client support to its customers, and the highest level
of analytical testing technology available in the industry.”
For more information, please visit
www.eurofinsus.com
Notes for the editor:Eurofins – a global leader in
bio-analysisEurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics and central
laboratory services.
With over 15,000 staff in more than 190 laboratories across 37
countries, Eurofins offers a portfolio of over 100,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the NYSE
Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
Eurofins Scientific, Inc.Phone: 515.280.8378E-mail:
info@eurofinsus.comUS Corporate Development2200 Rittenhouse Street,
Suite 175Des Moines, IA 50321
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024